Loading clinical trials...
Loading clinical trials...
A Multicenter, Open-label, Phase II Clinical Study of SHR-4849 Injection Combined With Other Antineoplastic Drugs in Patients With Malignant Solid Tumors
Conditions
Interventions
SHR-4849、SHR-1316、SHR-8068、BP102、carboplatin、cisplatin
Locations
1
China
Affiliated Cancer Hospital of Shandong First Medical University
Jinan, Shandong, China
Start Date
July 8, 2025
Primary Completion Date
December 1, 2028
Completion Date
December 1, 2028
Last Updated
March 3, 2026
NCT06658951
NCT06629584
NCT06717750
NCT06737731
NCT07292402
NCT02421380
Lead Sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions